Bank of Montreal Can trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 67.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,612 shares of the company’s stock after selling 43,249 shares during the quarter. Bank of Montreal Can’s holdings in Neurocrine Biosciences were worth $1,816,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Enterprise Financial Services Corp lifted its position in shares of Neurocrine Biosciences by 9,375.0% during the 1st quarter. Enterprise Financial Services Corp now owns 6,064 shares of the company’s stock valued at $535,000 after acquiring an additional 6,000 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Neurocrine Biosciences by 530.0% during the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 25,010 shares of the company’s stock valued at $2,203,000 after acquiring an additional 21,040 shares during the last quarter. Virginia Retirement Systems ET AL lifted its position in shares of Neurocrine Biosciences by 43.5% during the 1st quarter. Virginia Retirement Systems ET AL now owns 8,900 shares of the company’s stock valued at $784,000 after acquiring an additional 2,700 shares during the last quarter. Steinberg Global Asset Management lifted its position in shares of Neurocrine Biosciences by 2.7% during the 1st quarter. Steinberg Global Asset Management now owns 15,923 shares of the company’s stock valued at $1,403,000 after acquiring an additional 412 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. lifted its position in shares of Neurocrine Biosciences by 9.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 3,278 shares of the company’s stock valued at $289,000 after acquiring an additional 281 shares during the last quarter. 99.57% of the stock is owned by institutional investors and hedge funds.

In other news, insider Haig P. Bozigian sold 34,547 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $75.51, for a total value of $2,608,643.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

NBIX opened at $79.03 on Monday. The firm has a market capitalization of $7.21 billion, a PE ratio of 359.23 and a beta of 1.73. Neurocrine Biosciences, Inc. has a 12-month low of $64.72 and a 12-month high of $126.98. The company has a quick ratio of 8.61, a current ratio of 8.79 and a debt-to-equity ratio of 0.96.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.07). The business had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. Neurocrine Biosciences’s revenue for the quarter was up 94.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.47) EPS. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post -0.24 EPS for the current fiscal year.

A number of equities research analysts have recently commented on NBIX shares. JPMorgan Chase & Co. upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $100.00 to $106.00 in a research report on Monday, April 22nd. BidaskClub downgraded Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, February 9th. ValuEngine downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Needham & Company LLC downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Neurocrine Biosciences in a research report on Wednesday, February 6th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $103.42.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2019/05/20/neurocrine-biosciences-inc-nbix-position-cut-by-bank-of-montreal-can.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Story: Google Finance Portfolio

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.